TG Therapeutics (TGTX) Plans Conf. Call for GENUINE Phase 3 Update
- Wall St. slips as countdown to Trump's swearing-in begins
- Netflix, Inc. (NFLX) Tops Q4 EPS by 1c; Subs Beat Views
- Apple (AAPL) PT Raised to $140 at BofA/Merrill Lynch; iPhone 8 Will be 'Super-Long' Cycle
- Morgan Stanley Upgrades Tesla Motors (TSLA) to Overweight
- CP's (CP) Outgoing CEO Hunter Harrison, Activist Paul Hilal Said Set to Target CSX Corp. (CSX)
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
TG Therapeutics, Inc. (Nasdaq: TGTX), announced that a conference call will be held tomorrow, Thursday, October 13, 2016 at 8:30am ET to provide an update on the GENUINE Phase 3 Trial. Michael S. Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics GENUINE Update Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce details of the amendments in a press release to be issued prior to the call.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viper Energy Partners (VNOM) Prices Upsized $131.75M Offering of Common Stock
- Viper Energy Partners (VNOM) Offers Q4 Operational Results, Update on Recent Acquisitions
- Cullen/Frost Bankers (CFR) Announces Jack Wood and Royce Caldwell to Leave Board of Directors
Create E-mail Alert Related CategoriesConference Calls, Corporate News
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!